Microhematuria assessment an IBCN consensus—Based upon a critical review of current guidelines
Bernd J. Schmitz‐Dräger, Lambertus A. Kiemeney(Radboud University Nijmegen), Peter J. Goebell(Universitätsklinikum Erlangen), Antonia Vlahou(Academy of Athens), Tahlita C.M. Zuiverloon(Erasmus MC), Abhishek Srivastava(Albert Einstein College of Medicine), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), T. Todenhöfer(University of British Columbia), H. Barton Grossman(The University of Texas MD Anderson Cancer Center), Ellen C. Zwarthoff(Erasmus MC), Marta Sänchez‐Carbayo(Spanish National Cancer Research Centre), Amanda F. Saltzman(Children's Hospital Colorado), M’Liss A. Hudson(Special Health Resources for Texas), Morgan Rouprêt(Sorbonne Université), Shahrokh F. Shariat(Universitätszahnklinik Wien), Roland Seiler(University of British Columbia), Mark Schoenberg(Montefiore Medical Center), Eva Charlotte Kuckuck(Schön Klinik Nürnberg Fürth), Bas W.G. van Rhijn(The Netherlands Cancer Institute), Lenuta-A. Brünn(Francis Hospital)
Urologic Oncology Seminars and Original Investigations
September 16, 2016
Cited by 33
Related Papers
Common variants conferring risk of schizophrenia
|Nature|2009|1.7k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo.
|Proceedings of the National Academy of Sciences|1989|493